Zacks Investment Research on MSN
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm ...
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $60.62, moving -2.38% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.55% for ...
CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...
CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...
CRISPR stock is a bold investment in the future. Beyond the valuation, thematically and based on current market dynamics, I consider this a venture-style winner. Just because CRISPR stock may be a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback